Biomarkers of response to nae inhibitors
AssigneeMillennium Pharmaceuticals, Inc.
InventorsStephen J. Blakemore, Bin Li, George J. Mulligan, Matthew C. Schu, Peter G. Smith
Life of this patent
Estimating the term…
Abstract
Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
Claims28
A method for identifying a cancer patient for treatment with a NEDD8-activating enzyme (NAE) inhibitor comprising:
- a) measuring at least one characteristic of at least one marker associated with at least one marker gene in a patient sample comprising tumor cells, wherein the at least one characteristic is selected from the group consisting of size, sequence, composition and amount;
- b) identifying whether the at least one characteristic measured in step a) is informative for outcome upon treatment with the NAE inhibitor, wherein the NAE inhibitor is ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate;
- and
- c) identifying the patient for treatment with the NAE inhibitor if the informative characteristic indicates that the tumor cells comprise at least one marker gene whose mutational status indicates a favorable outcome to NAE inhibition therapy,
- wherein the at least one marker gene is a tumor suppressor with a relationship to the activity of a cullin ring ligase and the mutational status is mutant.
-3. (canceled)
(canceled)
(canceled)
-14. (canceled)
-26. (canceled)
A kit comprising a reagent to measure at least one characteristic of at least one marker in a patient sample, wherein the at least one characteristic is selected from the group consisting of size, sequence, composition and amount, wherein the at least one marker corresponds to at least one marker gene is a tumor suppressor with a relationship to the activity of a cullin ring ligase.
(canceled)
-35. (canceled)
-39. (canceled)
A method for paying for the treatment of cancer with an NAE inhibitor comprising:
- a) recording the mutational status of at least one marker gene in a patient sample comprising tumor cells, and
- b) authorizing payment of the NAE inhibitor treatment if the mutational status indicates a favorable outcome,
- wherein the at least one marker gene is selected from the group consisting of NF2, SMAD4, KDM6A, and FBXW7 and the mutational status is mutant.
-42. (canceled)
A method for treating a cancer patient with a therapeutic regimen comprising an NAE inhibitor, comprising:
- a) using the mutational status of at least one marker gene of a patient's tumor, wherein the at least one marker gene is selected from the group consisting of NF2, SMAD4, KDM6A and FBXW7, to select for treatment a patient who is expected to have a favorable outcome with the therapeutic regimen, and
- b) treating the cancer patient with the NAE inhibitor, wherein the NAE inhibitor is a 1-substituted methyl sulfamate.
Dependencies are inferred from the claim text.